Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Misdemeanor Charges Drive FDA's Park Doctrine Enforcement

This article was originally published in The Tan Sheet

Executive Summary

FDA will push harder for federal prosecutors to take misdemeanor cases as the agency ramps up use of the Park Doctrine and strict liability statutes to prosecute corporate executives and others

You may also be interested in...



Supplement Sector Regulatory Milestones: Senators' Enforcement Push, GNC Supply Chain Guidelines

Former FDA OCI Director George Karavetsos says GNC's supply chain guidelines for its vendors is the industry standard, while Sens. Hatch and Heinrich exceeded all standards by recommending DoJ get tougher on firms violating FDA supplement product regulations,

Senators Push Park Doctrine Prosecution For Spiked Supplement ‘Criminal Endeavors’

Key industry allies say they are “deeply concerned” about “blatant criminal activity” in products marketed as supplements but containing anabolic steroids or other drugs. “Bring a few of these actions and you scare people into the idea that … you could actually go to jail,” says attorney Frederick Stearns.

Senators Push Park Doctrine Prosecution For Spiked Supplement ‘Criminal Endeavors’

Key industry allies say they are “deeply concerned” about “blatant criminal activity” in products marketed as supplements but containing anabolic steroids or other drugs. “Bring a few of these actions and you scare people into the idea that … you could actually go to jail,” says attorney Frederick Stearns.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel